These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8640766)

  • 21. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
    Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
    Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
    Harker WG; Sikic BI
    Cancer Res; 1985 Sep; 45(9):4091-6. PubMed ID: 4028002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
    Isonishi S; Saitou M; Saitou M; Yasuda M; Tanaka T
    Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line.
    Nakagawa M; Enokida H; Gotanda T; Tachiwada T; Imazono Y; Kubo H; Nishiyama K; Suzuki S; Inomata K; Kishiye T
    Aktuelle Urol; 2003 Jul; 34(4):250-2. PubMed ID: 14566676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
    Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
    Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis.
    Jaffrézou JP; Chen KG; Durán GE; Kühl JS; Sikic BI
    J Natl Cancer Inst; 1994 Aug; 86(15):1152-8. PubMed ID: 8028036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical genetic analysis of indanocine resistance in human leukemia.
    Hua XH; Genini D; Gussio R; Tawatao R; Shih H; Kipps TJ; Carson DA; Leoni LM
    Cancer Res; 2001 Oct; 61(19):7248-54. PubMed ID: 11585762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
    Ogretmen B; McCauley MD; Safa AR
    Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
    Duan Z; Feller AJ; Penson RT; Chabner BA; Seiden MV
    Clin Cancer Res; 1999 Nov; 5(11):3445-53. PubMed ID: 10589757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line.
    Le Moyec L; Tatoud R; Degeorges A; Calabresse C; Bauza G; Eugène M; Calvo F
    Cancer Res; 1996 Aug; 56(15):3461-7. PubMed ID: 8758912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
    Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW
    Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission.
    Harker WG; Bauer D; Etiz BB; Newman RA; Sikic BI
    Cancer Res; 1986 May; 46(5):2369-73. PubMed ID: 3754487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter.
    Gosland M; Tsuboi C; Hoffman T; Goodin S; Vore M
    Cancer Res; 1993 Nov; 53(22):5382-5. PubMed ID: 8106146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine.
    Gosland MP; Gillespie MN; Tsuboi CP; Tofiq S; Olson JW; Crooks PA; Aziz SM
    Cancer Chemother Pharmacol; 1996; 37(6):593-600. PubMed ID: 8612315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
    Wiesen KM; Xia S; Yang CP; Horwitz SB
    Cancer Lett; 2007 Nov; 257(2):227-35. PubMed ID: 17869412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.